Targeting Siglec-E facilitates tumor vaccine-induced antitumor immunity in renal carcinoma
Background Siglec-E is an immune checkpoint inhibitory molecule. Expression of Siglec-E on the immune cells has been shown to promote tumor regression. This study aimed to develop an adenovirus (Ad) vaccine targeting Siglec-E and carbonic anhydrase IX (CAIX) (Ad-Siglec-E/CAIX) and to evaluate its po...
Saved in:
Main Authors: | Yuchen Zhang, Junnian Zheng, Li Sun, Guangya Zhao, Yingxiang Shao, Bowen Lu, Jiage Ding, Yanyan Zheng, Renjin Chen, Dafei Chai, Jiawei Wang, Zichun Zhang, Xiaohui Xie |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2025-01-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/13/1/e010521.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Roles of Siglec7 and Siglec9 on Natural Killer Cells in Virus Infection and Tumour Progression
by: Yayun Zheng, et al.
Published: (2020-01-01) -
Comprehensive Modular Synthesis of Ganglioside Glycans and Evaluation of their Binding Affinities to Siglec‐7 and Siglec‐9
by: Avijit K. Adak, et al.
Published: (2025-01-01) -
Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma
by: Qing Zhang, et al.
Published: (2017-01-01) -
SIGLEC11 promotes M2 macrophage polarization through AKT–mTOR signaling and facilitates the progression of gastric cancer
by: Chen Li, et al.
Published: (2025-01-01) -
Immuno-PET Imaging of Siglec-15 Using the Zirconium-89-Labeled Therapeutic Antibody, NC318
by: Elaine M. Jagoda, et al.
Published: (2023-01-01)